A PHASE 2/3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DNL310 VS IDURSULFASE IN PEDIATRIC PARTICIPANTS WITH NEURONOPATHIC OR NON-NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II

Registry ID

DNLI-E-0007

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

DENALI THERAPEUTICS INC.

Start date

2023-09-18

Last update

2022-06-07

Conditions

• MUCOPOLYSACCHARIDOSIS TYPE II (MPS II)

Related clinical trials

• EFFECT OF ADALIMUMAB ON MUSCULOSKELETAL DISEASE IN MUCOPOLYSACCHARIDOSIS TYPES I, II, IVA AND VI
• AN OPEN-LABEL EXTENSION TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DNL310 IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) FROM STUDY DNLI-E-0002 OR STUDY DNLI-E-0007

View on source registry